• Live webinar to be held by Prof. Luis Blanco, inventor of TthPrimPol, the underlying enzyme that enables primer-free WGA
• TruePrime(TM) Technology provides significant advantages including the absence of any primer induced artifacts and insensitivity to external DNA contaminations
Madrid, Spain and Heidelberg, Germany, March 11, 2015 - SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that it will host a live webinar entitled, ‘TruePrime(TM), the revolution in DNA amplification - Primer-free Whole Genome Amplification (WGA)’ on Wednesday, March 18, starting at 5:00PM CET (12:00AM EDT).
During the complimentary webinar Prof. Luis Blanco, will offer his expert guidance on the application of TruePrime(TM). Prof. Blanco, inventor of the underlying enzyme that enables primer-free whole genome amplification, is Research Professor at the Severo Ochoa Centre for Molecular Biology (CBMSO) of the Spanish National Research Council (CSIC) in Madrid.
‘I am very proud that my work has found its way into a product that can help researchers in molecular biology to significantly improve workflows and results especially in next generation sequencing (NGS) applications,’ Prof. Blanco commented. ‘Single cell analysis with NGS has become one of the most exciting applications in molecular biology today. By avoiding artefacts that normally occur when using standard amplification technologies, TruePrime allows for a multitude of applications including, for example, analyzing cancer related mutations in cells taken from different locations in a tumor, a must in Oncology or Personalized/Precision Medicine.’
The webinar will provide information on fields of application for this revolutionary novel multiple displacement amplification (MDA) method and how it can significantly improve results. The MDA method is based on the combination of the recently discovered TthPrimPol and Phi29 DNA polymerase for the primer-free amplification of genomic DNA from the smallest amounts of samples down to single cells.
For more information and to register for the webinar, visit http://bit.do/trueprime_webinar. The event will also be recorded and available for on-demand viewing at www.sygnis.com.
About Prof. Luis Blanco
Internationally, Prof. Blanco is a highly respected expert in DNA polymerases and their applications in biotechnology. He has identified and described several DNA polymerases, including the molecule in the bacteriophage phi29, as well as the human Pol ?, Pol µ and PrimPol enzymes.
Prof. Blanco has headed a number of national and international research projects and is the author of over a hundred papers published in major international scientific journals. November 2014 he was granted the prestigious Carmen y Severo Ochoa Molecular Biology Research Award. The prize, awarded by the Carmen y Severo Ochoa Foundation, recognizes Prof. Blanco’s research in the field of molecular biology. Prof. Blanco is co-founder of X-Pol Biotech, which merged with SYGNIS in 2012. He is currently one of the main shareholders and a scientific advisor in this company.
About TruePrime(TM)
TruePrime(TM) is the brand name of a revolutionary novel multiple displacement amplification (MDA) technology and one of the key products in SYGNIS’ portfolio. TruePrime(TM) is based on the combination of the recently discovered DNA primase ‘TthPrimPol’ and the extremely processive and high-fidelity Phi29 polymerase to amplify uniformly total genomic DNA for a multitude of applications including next generation sequencing and single cell analysis. The extraordinary strand-displacement capacity of Phi29 polymerase allows TthPrimPol to generate new primers on the displaced strands that are extended by Phi29 DNA pol, resulting in exponential isothermal DNA amplification without the need of any synthetic random primers.
The resulting benefits of this innovative approach are enormous and include the complete absence of common artifacts linked to the use of oligonucleotides, a reduced amplification bias in genome coverage compared to methods using random synthetic primers, a surpassing reliability as contaminating DNA is not amplified and an exquisite reproducibility when DNA is amplified from single mammalian cells. Moreover, TruePrime(TM) shows superior sensitivity, is easy to use and works perfectly well with all commonly used NGS platforms such as Illumina and Ion Torrent.
For further information please contact:
SYGNIS AG
Pilar de la Huerta
CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com
MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 30
Email: raimund.gabriel@mc-services.eu
About SYGNIS AG: www.sygnis.com
Following the merger with X-Pol Biotech in 2012, SYGNIS specializes on the development and commercialization of products for DNA amplification and sequencing. SYGNIS AG, listed at the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), has a commercial product for whole genome DNA amplification, SensiPhi (R) , licensed to an industry leading partner and is currently developing its own TruePrime(TM) product line based on its proprietary TruePrime(TM) technology for use in the fast growing field of Next Generation Sequencing. The first products for single cell as well as whole genome DNA amplification were launched beginning 2015.
Help employers find you! Check out all the jobs and post your resume.
